Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SEMA4A Biologics Sequence Review Report 2026: Semaphorin-4A Similarity and Patent-Risk Signals
8 min read
SEMA4A Biologics Sequence Review Report 2026: Semaphorin-4A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3G Biologics Sequence Review Report 2026: Semaphorin-3G Similarity and Patent-Risk Signals
8 min read
SEMA3G Biologics Sequence Review Report 2026: Semaphorin-3G Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA4C Biologics Sequence Review Report 2026: Semaphorin-4C Similarity and Patent-Risk Signals
8 min read
SEMA4C Biologics Sequence Review Report 2026: Semaphorin-4C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3F Biologics Sequence Review Report 2026: Semaphorin-3F Similarity and Patent-Risk Signals
8 min read
SEMA3F Biologics Sequence Review Report 2026: Semaphorin-3F Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3D Biologics Sequence Review Report 2026: Semaphorin-3D Similarity and Patent-Risk Signals
8 min read
SEMA3D Biologics Sequence Review Report 2026: Semaphorin-3D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3E Biologics Sequence Review Report 2026: Semaphorin-3E Similarity and Patent-Risk Signals
8 min read
SEMA3E Biologics Sequence Review Report 2026: Semaphorin-3E Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3E protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3C Biologics Sequence Review Report 2026: Semaphorin-3C Similarity and Patent-Risk Signals
8 min read
SEMA3C Biologics Sequence Review Report 2026: Semaphorin-3C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARF1 Biologics Sequence Review Report 2026: Scavenger receptor class F member 1 Similarity and Patent-Risk Signals
8 min read
SCARF1 Biologics Sequence Review Report 2026: Scavenger receptor class F member 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3B Biologics Sequence Review Report 2026: Semaphorin-3B Similarity and Patent-Risk Signals
8 min read
SEMA3B Biologics Sequence Review Report 2026: Semaphorin-3B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3A Biologics Sequence Review Report 2026: Semaphorin-3A Similarity and Patent-Risk Signals
8 min read
SEMA3A Biologics Sequence Review Report 2026: Semaphorin-3A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARF2 Biologics Sequence Review Report 2026: Scavenger receptor class F member 2 Similarity and Patent-Risk Signals
8 min read
SCARF2 Biologics Sequence Review Report 2026: Scavenger receptor class F member 2 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMP17 Biologics Sequence Review Report 2026: Matrix metalloproteinase-17 Similarity and Patent-Risk Signals
8 min read
MMP17 Biologics Sequence Review Report 2026: Matrix metalloproteinase-17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of MMP17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →